Get more information on Dry Age-Related Macular Degeneration Market - Request Sample Report
The Dry Age-Related Macular Degeneration Market Size was valued at USD 4.83 billion in 2023 and is expected to reach USD 10.57 billion by 2032 and grow at a CAGR of 9.1% over the forecast period 2024-2032.
The dry age-related macular degeneration market is expected to boom, considering an array of factors that include new products and a strong product pipeline. The mounting incidence of AMD, especially in geriatric populations, would catapult the market in this space. In 2022, Americans aged 65 and older numbered 58 million. By 2050, this number is expected to reach 82 million, up substantially by 47%. This demographic shift accentuates the ever-growing requirement for treatments of dry age-related macular degeneration owing to the advanced age at an unprecedented rate in the U.S. population.
A combination of lifestyle and dietary factors also contributes to the rise in dry age-related macular degeneration, including smoking, consumption of alcohol, and physical inactivity, among others. Lifestyle and dietary factors lead to an increased risk of developing dry age-related macular degeneration, thereby fueling market demand. The market also drives mainly through an intense focus on R&D, observed in the stepwise launch of dry age-related macular degeneration drugs. Improvements in reimbursement policies enhance access and affordability to a supply of therapeutic AMD drugs, thereby promoting growth in the market.
The vast potential for markets in developing countries is significant, as the dry age-related macular degeneration market is growing at an incredible rate. Besides this, the emphasis of focus is gradually moving towards the discovery of novel drug modalities to target each type of AMD and therefore comes with new prospects for innovation and expansion. Still, the market remains quite challenging, with off-label use of drugs such as Avastin, limiting the demand for established therapeutics when treating dry age-related macular degeneration. Intravitreal injections periodically also mean that patients have a high treatment burden, keeping this market somewhat capped in growth.
Dry age-related macular degeneration is going to be one major growth area, mainly due to the steadily and rapidly increasing elderly population, in addition to a higher incidence of dry age-related macular degeneration. New treatments are being found to treat dry age-related macular degeneration; more and more clinical trials are being conducted, which will support the growth of this segment as one of the strong growth drivers in the comprehensive scope of the dry age-related macular degeneration market.
Drivers
Growing Geriatric Population, Increased Healthcare Spending, and Advances in Long-Acting Therapies
The rapidly growing worldwide population of geriatric patients is mainly driving the increasing incidence of Dry AMD. A UN report published in December 2020 lists population figures for those aged 65 years or older as having grown to 727 million in 2020 and is expected to double to 1.5 billion by 2050. The proportion of people above age 65 years is going to increase from 9.3% in 2020 to 16% in 2050, with China alone holding a share of its increased elderly population growth from 12% to 26% within the same period. The primary influence for the increasing prevalence of age-related macular degeneration, which encompasses Dry AMD, is the rapidly growing elderly population, especially in developed and emerging markets.
Increasing health expenditure is one of the catalysts driving the market forward as low- and middle-income countries invest more in health. In 2019, the World Health Organization published a report, which stated that healthcare spending rose 6% in low and middle-income countries and 4% in high-income countries with evolving funding models. However, only just short of 40% of government expenditure goes into primary health care indicating further investment in treatment of AMD for age-related conditions.
Another major factor is that long-acting anti-VEGF therapies are a huge relief from the burden of repeated intraocular injections. The sustained drug delivery with drugs such as Beovu and Vabysmo would enhance compliance and outcomes, thus driving growth in the market. Biosimilars, including BYOOVIZ, approved in 2021, continue to help drive the market forward by offering affordable treatment alternatives.
Restraints
High Treatment Burden and Non-Adherence
Limited Availability of Approved Treatments
By Stages
Intermediate dry age-related macular degeneration held the largest share of the market in 2023 in Dry AMD. This is the most common stage with which to start as some symptoms start occurring, but the disease has not yet reached its worst stage. This leads to a massive market share of more than 45% from Intermediate Dry AMD. This has also been made prominent by the increasing awareness and early diagnosis at this stage, with many patients receiving treatment to slow the progression to late-stage AMD. The Late Dry Age-Related Macular Degeneration segment is expected to be the fastest-growing, at an 8% growth rate. This is because the number of patients progressing to late-stage Dry AMD is increasing, plus the emergence of new therapies addressing the advanced stages of dry age-related macular degeneration.
By Age Group
The Above 60-year-old age group was the market leader in 2023 securing more than 50% share of the Dry AMD market. Given that the condition is strongly related to old age, those above 60 years have accounted for the highest incidence rates. The aging population, particularly those over 60 years across developed countries and specifically amplified by lifestyle risk factors, explains much of the demand for Dry AMD therapy within this segment. This is going to be the dominant age group, given the aging of the global population. The Above 75 Years segment is anticipated to grow at the fastest rate, through a CAGR of more than 9%. As life expectancy increases, the prevalence of AMD for this elderly population is projected to rise, and thus demand for Dry AMD treatments will increase.
By Diagnosis And Treatment
The Treatment segment held more than 65% of the overall market share in the year 2023. Intermediate Dry AMD treatment is rapidly progressing with advanced therapeutic options using vitamins and antioxidants, in addition to new treatment options, thus driving growth in this segment. A plethora of therapies are under investigation for Dry AMD, thus constantly evolving the treatment landscape of the disease, which further supports growth in the market share of this segment. The Diagnosis segment is likely to witness a growth rate of around 7.5%. Advanced technologies like OCT, which place increased significance on early diagnosis in the case of Dry AMD, are propelling the rapidly growing trend in this segment.
The Dry Age-Related Macular Degeneration market was dominated by North America in 2023 with a 46.3% share. Strong awareness levels and well-established healthcare infrastructure are the key factors in this region. According to the American Academy of Ophthalmology, approximately 1.5 million Americans suffer from late-stage AMD, whereas 18.3 million cases are diagnosed with early-stage AMD. Enhanced public awareness has increased earlier diagnosis and treatment, resulting in increased market demand. The market share accounted for a significant volume with 92.1% of the total North American market in 2023 due to the high penetration of developed eye care facilities.
Europe is one of the key growth regions in terms of Dry AMD, as the aging population only looks upwards. According to an article by the British Journal of Ophthalmology, 67 million people in the EU are afflicted with AMD. The number will increase by 15% by 2050 as a result of demographic changes in the aged population. Advancement of life and living standards has increased the treatment demand for Dry AMD in the region.
Huge growth is anticipated from the Asia Pacific region, where a vast geriatric population and an increasing disease burden are expected to fuel growth in the coming years. Government initiatives in improving the affordability of costly anti-VEGF products also support market growth, and Asia Pacific is considered a lucrative region for Dry AMD treatments in the future.
Need any customization research on Dry Age-Related Macular Degeneration Market - Enquiry Now
Treatment Providers
Pfizer Inc.
Amgen Inc.
Biogen
F. Hoffmann-La Roche Ltd
Samsung Bioepis
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Inc.
Allergan plc
Alimera Sciences Inc.
Phio Pharmaceuticals Corp
Iveric Bio
Belite Bio Inc.
Diagnosis Providers
Bausch Health Companies Inc.
Alimera Sciences Inc.
Ocumension Therapeutics Co. Ltd
Iveric Bio
Device Manufacturers
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Biogen
Eyestem Research Pvt Ltd
Kubota Vision Inc.
In July 2024, Genentech (Roche) relaunched Susvimo (100 mg/mL ranibizumab injection) in the U.S. for intravitreal use through an ocular implant, aimed at treating neovascular or 'wet' age-related macular degeneration (nAMD).
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 4.83 Billion |
| Market Size by 2032 | US$ 10.57 Billion |
| CAGR | CAGR of 9.1% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • by Stages (Early AMD, Intermediate AMD, Late AMD) • by End User (Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes, Others) • by Age Group (Above 40 Years, Above 60 Years, Above 75 Years) • by Diagnosis & Treatment (Treatment, Diagnosis) • by Route of Administration (Oral, Injectables) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bayer AG, Pfizer Inc., Amgen Inc., Biogen, Novartis AG, F. Hoffmann-La Roche Ltd, Samsung Bioepis, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceuticals Inc., Allergan plc , Alimera Sciences Inc. , Phio Pharmaceuticals Corp , Iveric Bio , Belite Bio Inc. , Ocumension Therapeutics Co. Ltd, Eyestem Research Pvt Ltd, Kubota Vision Inc and other players |
| Key Drivers | • Growing Geriatric Population, Increased Healthcare Spending, and Advances in Long-Acting Therapies |
| RESTRAINTS | • High Treatment Burden and Non-Adherence • Limited Availability of Approved Treatments |
Ans: The Dry Age-Related Macular Degeneration Market is to grow at a CAGR of 9.1% over the forecast period 2024-2032.
Ans: The expected value of the Dry Age-Related Macular Degeneration Market is USD 10.57 billion by 2032.
Ans: The major players are Bayer AG, Pfizer Inc., Amgen Inc., Biogen, Novartis AG, F. Hoffmann-La Roche Ltd, Samsung Bioepis, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceuticals Inc., Allergan plc , Alimera Sciences Inc. , Phio Pharmaceuticals Corp , Iveric Bio , Belite Bio Inc. , Ocumension Therapeutics Co. Ltd, Eyestem Research Pvt Ltd, Kubota Vision Inc and other players
High Treatment Burden and Non-Adherence
Limited Availability of Approved Treatments
Ans: Growing Geriatric Population, Increased Healthcare Spending, and Advances in Long-Acting Therapies
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Treatment Modalities Volume, by Region (2020-2032)
5.4 Healthcare Spending on AMD Treatments, by Region (2023)
5.5 Clinical Trials and Research Investments (2023)
5.6 Demographic Insights and Geriatric Population Trends (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Dry Age-Related Macular Degeneration Market Segmentation, by Stages
7.1 Chapter Overview
7.2 Early Age-Related Macular Degeneration
7.2.1 Early Age-Related Macular Degeneration Market Trends Analysis (2020-2032)
7.2.2 Early Age-Related Macular Degeneration Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Intermediate Age-Related Macular Degeneration
7.3.1 Intermediate Age-Related Macular Degeneration Market Trends Analysis (2020-2032)
7.3.2 Intermediate Age-Related Macular Degeneration Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Late Age-Related Macular Degeneration
7.4.1 Late Age-Related Macular Degeneration Market Trends Analysis (2020-2032)
7.4.2 Late Age-Related Macular Degeneration Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Dry Age-Related Macular Degeneration Market Segmentation, By Age Group
8.1 Chapter Overview
8.2 Above 40 Years
8.2.1 Above 40 Years Market Trends Analysis (2020-2032)
8.2.2 Above 40 Years Market Size Estimates And Forecasts To 2032 (USD Billion)
8.3 Above 60 Years
8.3.1 Above 60 Years Market Trends Analysis (2020-2032)
8.3.2 Above 60 Years Market Size Estimates And Forecasts To 2032 (USD Billion)
8.4 Above 75 Years
8.4.1 Above 75 Years Market Trends Analysis (2020-2032)
8.4.2 Above 75 Years Market Size Estimates And Forecasts To 2032 (USD Billion)
9. Dry Age-Related Macular Degeneration Market Segmentation, By Diagnosis And Treatment
9.1 Chapter Overview
9.2 Treatment
9.2.1 Treatment Market Trends Analysis (2020-2032)
9.2.2 Treatment Market Size Estimates And Forecasts To 2032 (USD Billion)
9.3 Diagnosis
9.3.1 Diagnosis Market Trends Analysis (2020-2032)
9.3.2 Diagnosis Market Size Estimates And Forecasts To 2032 (USD Billion)
10. Dry Age-Related Macular Degeneration Market Segmentation, By Route Of Administration
10.1 Chapter Overview
10.2 Oral
10.2.1 Oral Market Trends Analysis (2020-2032)
10.2.2 Oral Market Size Estimates And Forecasts To 2032 (USD Billion)
10.3 Injectables
10.3.1 Injectables Market Trends Analysis (2020-2032)
10.3.2 Injectables Market Size Estimates And Forecasts To 2032 (USD Billion)
11. Dry Age-Related Macular Degeneration Market Segmentation, By End-user
11.1 Chapter Overview
11.2 Hospital & Clinics
11.2.1 Hospital & Clinics Market Trends Analysis (2020-2032)
11.2.2 Hospital & Clinics Market Size Estimates And Forecasts To 2032 (USD Billion)
11.3 Diagnostic Centers
11.3.1 Diagnostic Centers Market Trends Analysis (2020-2032)
11.3.2 Diagnostic Centers Market Size Estimates And Forecasts To 2032 (USD Billion)
11.4 Academic Research Institutes
11.4.1 Academic Research Institutes Market Trends Analysis (2020-2032)
11.4.2 Academic Research Institutes Market Size Estimates And Forecasts To 2032 (USD Billion)
11.5 Others
11.5.1 Others Market Trends Analysis (2020-2032)
11.5.2 Others Market Size Estimates And Forecasts To 2032 (USD Billion)
12. Regional Analysis
12.1 Chapter Overview
12.2 North America
12.2.1 Trends Analysis
12.2.2 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.2.3 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.2.4 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.2.5 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.2.6 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.2.7 North America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.2.8 USA
12.2.8.1 USA Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.2.8.2 USA Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.2.8.3 USA Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.2.8.4 USA Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.2.8.5 USA Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.2.9 Canada
12.2.9.1 Canada Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.2.9.2 Canada Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.2.9.3 Canada Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.2.9.4 Canada Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.2.9.5 Canada Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.2.10 Mexico
12.2.10.1 Mexico Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.2.10.2 Mexico Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.2.10.3 Mexico Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.2.10.4 Mexico Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.2.10.5 Mexico Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Trends Analysis
12.3.1.2 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.3.1.3 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.4 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.5 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.6 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.7 Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.1.8 Poland
12.3.1.8.1 Poland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.8.2 Poland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.8.3 Poland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.8.4 Poland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.8.5 Poland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.1.9 Romania
12.3.1.9.1 Romania Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.9.2 Romania Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.9.3 Romania Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.9.4 Romania Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.9.5 Romania Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.1.10 Hungary
12.3.1.10.1 Hungary Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.10.2 Hungary Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.10.3 Hungary Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.10.4 Hungary Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.10.5 Hungary Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.1.11 Turkey
12.3.1.11.1 Turkey Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.11.2 Turkey Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.11.3 Turkey Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.11.4 Turkey Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.11.5 Turkey Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.1.12 Rest Of Eastern Europe
12.3.1.12.1 Rest Of Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.1.12.2 Rest Of Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.1.12.3 Rest Of Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.1.12.4 Rest Of Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.1.12.5 Rest Of Eastern Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2 Western Europe
12.3.2.1 Trends Analysis
12.3.2.2 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.3.2.3 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.4 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.5 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.6 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.7 Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.8 Germany
12.3.2.8.1 Germany Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.8.2 Germany Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.8.3 Germany Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.8.4 Germany Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.8.5 Germany Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.9 France
12.3.2.9.1 France Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.9.2 France Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.9.3 France Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.9.4 France Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.9.5 France Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.10 UK
12.3.2.10.1 UK Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.10.2 UK Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.10.3 UK Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.10.4 UK Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.10.5 UK Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.11 Italy
12.3.2.11.1 Italy Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.11.2 Italy Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.11.3 Italy Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.11.4 Italy Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.11.5 Italy Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.12 Spain
12.3.2.12.1 Spain Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.3.2.12.2 Spain Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.12.3 Spain Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.12.4 Spain Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.12.5 Spain Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.13 Netherlands
12.3.2.13.1 Netherlands Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.3.2.13.2 Netherlands Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.3.2.13.3 Netherlands Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.13.4 Netherlands Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.13.5 Netherlands Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.14 Switzerland
12.3.2.14.1 Switzerland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.3.2.14.2 Switzerland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.3.2.14.3 Switzerland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.14.4 Switzerland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.12.5 Switzerland Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.15 Austria
12.3.2.15.1 Austria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.3.2.15.2 Austria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.3.2.15.3 Austria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.15.4 Austria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.15.5 Austria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.3.2.16 Rest Of Western Europe
12.3.2.16.1 Rest Of Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.3.2.16.2 Rest Of Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.3.2.16.3 Rest Of Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.3.2.16.4 Rest Of Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.3.2.16.5 Rest Of Western Europe Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4 Asia Pacific
12.4.1 Trends Analysis
12.4.2 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.4.3 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.4 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.5 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.6 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.7 Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.8 China
12.4.8.1 China Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.8.2 China Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.8.3 China Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.8.4 China Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.8.5 China Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.9 India
12.4.9.1 India Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.9.2 India Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.9.3 India Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.9.4 India Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.9.5 India Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user(2020-2032) (USD Billion)
12.4.10 Japan
12.4.10.1 Japan Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.10.2 Japan Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.10.3 Japan Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.10.4 Japan Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.10.5 Japan Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.11 South Korea
12.4.11.1 South Korea Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.11.2 South Korea Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.11.3 South Korea Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.11.4 South Korea Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.11.5 South Korea Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.12 Vietnam
12.4.12.1 Vietnam Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.12.2 Vietnam Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.12.3 Vietnam Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment(2020-2032) (USD Billion)
12.4.12.4 Vietnam Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.12.5 Vietnam Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.13 Singapore
12.4.13.1 Singapore Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.13.2 Singapore Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.13.3 Singapore Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.13.4 Singapore Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.13.5 Singapore Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.14 Australia
12.4.14.1 Australia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.14.2 Australia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.4.14.3 Australia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment(2020-2032) (USD Billion)
12.4.14.4 Australia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.14.5 Australia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.4.15 Rest Of Asia Pacific
12.4.15.1 Rest Of Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.4.15.2 Rest Of Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group(2020-2032) (USD Billion)
12.4.15.3 Rest Of Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.4.15.4 Rest Of Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.4.15.5 Rest Of Asia Pacific Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5 Middle East And Africa
12.5.1 Middle East
12.5.1.1 Trends Analysis
12.5.1.2 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.5.1.3 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.1.4 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.5 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.6 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.7 Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.1.8 UAE
12.5.1.8.1 UAE Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.5.1.8.2 UAE Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.8.3 UAE Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.8.4 UAE Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.8.5 UAE Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.1.9 Egypt
12.5.1.9.1 Egypt Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.1.9.2 Egypt Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.1.9.3 Egypt Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.9.4 Egypt Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.9.5 Egypt Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.1.10 Saudi Arabia
12.5.1.10.1 Saudi Arabia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.1.10.2 Saudi Arabia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.1.10.3 Saudi Arabia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.10.4 Saudi Arabia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.10.5 Saudi Arabia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.1.11 Qatar
12.5.1.11.1 Qatar Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.1.11.2 Qatar Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.1.11.3 Qatar Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.11.4 Qatar Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.11.5 Qatar Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.1.12 Rest Of Middle East
12.5.1.12.1 Rest Of Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.1.12.2 Rest Of Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.1.12.3 Rest Of Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.1.12.4 Rest Of Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.1.12.5 Rest Of Middle East Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.2 Africa
12.5.2.1 Trends Analysis
12.5.2.2 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.5.2.3 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.2.4 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.2.5 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.2.6 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.2.7 Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.2.8 South Africa
12.5.2.8.1 South Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.2.8.2 South Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.2.8.3 South Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.2.8.4 South Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.2.8.5 South Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.2.9 Nigeria
12.5.2.9.1 Nigeria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.2.9.2 Nigeria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.2.9.3 Nigeria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.2.9.4 Nigeria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.2.9.5 Nigeria Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.5.2.10 Rest Of Africa
12.5.2.10.1 Rest Of Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.5.2.10.2 Rest Of Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.5.2.10.3 Rest Of Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.5.2.10.4 Rest Of Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.5.2.10.5 Rest Of Africa Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.6 Latin America
12.6.1 Trends Analysis
12.6.2 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.6.3 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.6.4 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.6.5 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.6.6 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.7 Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.6.8 Brazil
12.6.8.1 Brazil Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.6.8.2 Brazil Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.6.8.3 Brazil Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.6.8.4 Brazil Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.8.5 Brazil Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.6.9 Argentina
12.6.9.1 Argentina Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.6.9.2 Argentina Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.6.9.3 Argentina Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.6.9.4 Argentina Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.9.5 Argentina Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.6.10 Colombia
12.6.10.1 Colombia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages (2020-2032) (USD Billion)
12.6.10.2 Colombia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Age Group (2020-2032) (USD Billion)
12.6.10.3 Colombia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.6.10.4 Colombia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.10.5 Colombia Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
12.6.11 Rest Of Latin America
12.6.11.1 Rest Of Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Stages(2020-2032) (USD Billion)
12.6.11.2 Rest Of Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.11.3 Rest Of Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Diagnosis And Treatment (2020-2032) (USD Billion)
12.6.11.4 Rest Of Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By Route Of Administration (2020-2032) (USD Billion)
12.6.11.5 Rest Of Latin America Dry Age-Related Macular Degeneration Market Estimates And Forecasts, By End-user (2020-2032) (USD Billion)
13. Company Profiles
13.1 Bayer AG
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.2 Pfizer Inc.
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.3 Amgen Inc.
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.4 Novartis AG
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.5 Samsung Bioepis
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.6 F. Hoffmann-La Roche Ltd
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.7 Bausch Health Companies Inc.
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.8 Regeneron Pharmaceuticals Inc.
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.9 Santen Pharmaceuticals Inc.
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.10 Phio Pharmaceuticals Corp
13.12.1 Company Overview
13.12.2 Financial
13.12.3 Products/ Services Offered
13.12.4 SWOT Analysis
14. Use Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Stages
Early Age-Related Macular Degeneration
Intermediate Age-Related Macular Degeneration
Late Age-Related Macular Degeneration
By Age Group
Above 40 Years
Above 60 Years
Above 75 Years
By Diagnosis And Treatment
Treatment
Diagnosis
By Route Of Administration
Oral
Injectables
By End User
Hospital & Clinics
Diagnostic Centers
Academic Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Peptide Microarray Market size was estimated at USD 830.83 million in 2023 and is expected to reach USD 1245.37 million by 2032 with a growing CAGR of 4.6% during the forecast period of 2024-2032.
The Transfer Membrane Market size was estimated at USD 402.91 million in 2023 and is expected to reach USD 603.95 million by 2032 with a growing CAGR of 4.6% during the forecast period of 2024-2032.
The global Ultrasound Gels market, valued at USD 98.20 million in 2023, is projected to reach USD 129.61 million by 2032, growing at a compound annual growth rate (CAGR) of 3.24% during the forecast period.
Surgical Imaging Market was valued at USD 148 billion in 2023 and is expected to reach USD 340.5 billion by 2032 and grow at a CAGR of 9.7% from 2024 to 2032.
The Surgical Tables Market size was estimated at USD 1.49 billion in 2023 and is expected to reach USD 2.67 billion by 2032 at a CAGR of 6.7% during the forecast period of 2024-2032.
The CMO/CDMO Market Size was valued at USD 20.9 Billion in 2023 and is expected to reach USD 51 Billion by 2032, and grow at a CAGR of 10.4% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
